Equities Analysts Offer Predictions for AKRO FY2024 Earnings

Akero Therapeutics, Inc. (NASDAQ:AKRO) – Equities research analysts at HC Wainwright decreased their FY2024 earnings per share estimates for Akero Therapeutics in a note issued to investors on Monday, November 11th. HC Wainwright analyst E. Arce now expects that the company will post earnings per share of ($3.90) for the year, down from their previous estimate of ($3.44). HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Akero Therapeutics’ current full-year earnings is ($3.82) per share. HC Wainwright also issued estimates for Akero Therapeutics’ Q4 2024 earnings at ($1.13) EPS, Q1 2025 earnings at ($1.16) EPS, Q2 2025 earnings at ($1.19) EPS, Q3 2025 earnings at ($1.20) EPS, Q4 2025 earnings at ($1.22) EPS, FY2025 earnings at ($4.77) EPS, FY2026 earnings at ($3.91) EPS and FY2027 earnings at ($1.17) EPS.

Akero Therapeutics (NASDAQ:AKRO) last posted its quarterly earnings data on Friday, November 8th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.15).

Akero Therapeutics Stock Performance

Akero Therapeutics stock opened at $30.97 on Thursday. Akero Therapeutics has a fifty-two week low of $13.86 and a fifty-two week high of $37.00. The company has a debt-to-equity ratio of 0.05, a quick ratio of 24.89 and a current ratio of 17.25. The stock has a market cap of $2.16 billion, a P/E ratio of -8.26 and a beta of -0.26. The firm’s fifty day moving average price is $29.36 and its 200-day moving average price is $25.50.

Institutional Trading of Akero Therapeutics

A number of institutional investors have recently modified their holdings of AKRO. Janus Henderson Group PLC lifted its position in shares of Akero Therapeutics by 42.2% in the 1st quarter. Janus Henderson Group PLC now owns 6,121,970 shares of the company’s stock worth $154,589,000 after purchasing an additional 1,815,569 shares during the period. Price T Rowe Associates Inc. MD boosted its position in Akero Therapeutics by 10.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,060,479 shares of the company’s stock valued at $102,569,000 after acquiring an additional 384,555 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Akero Therapeutics by 19.0% during the 1st quarter. Vanguard Group Inc. now owns 3,669,923 shares of the company’s stock worth $92,702,000 after acquiring an additional 584,875 shares during the period. Baker BROS. Advisors LP lifted its position in Akero Therapeutics by 14.6% during the first quarter. Baker BROS. Advisors LP now owns 2,713,205 shares of the company’s stock valued at $68,536,000 after buying an additional 344,827 shares during the period. Finally, Redmile Group LLC boosted its holdings in shares of Akero Therapeutics by 67.5% during the 1st quarter. Redmile Group LLC now owns 1,858,702 shares of the company’s stock valued at $46,951,000 after buying an additional 749,226 shares in the last quarter.

Insider Activity

In other Akero Therapeutics news, CEO Andrew Cheng sold 1,738 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $26.18, for a total transaction of $45,500.84. Following the transaction, the chief executive officer now directly owns 605,417 shares in the company, valued at $15,849,817.06. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider Catriona Yale sold 5,200 shares of Akero Therapeutics stock in a transaction on Monday, August 26th. The shares were sold at an average price of $27.51, for a total value of $143,052.00. Following the transaction, the insider now directly owns 75,931 shares of the company’s stock, valued at $2,088,861.81. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Andrew Cheng sold 1,738 shares of the stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $26.18, for a total transaction of $45,500.84. Following the sale, the chief executive officer now directly owns 605,417 shares of the company’s stock, valued at $15,849,817.06. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 428,397 shares of company stock worth $12,997,971. 7.94% of the stock is currently owned by insiders.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.